Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
Delayed Japan Exchange  -  01:00 2022-12-01 am EST
2127.00 JPY   -0.05%
11/30Astellas Pharma Plans $360 Million Bond Sale
MT
11/18Aurobindo Pharma Arm Gets US FDA Nod for Amphotericin B Liposome
MT
11/17Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroesophageal Junction Cancers
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

US Court Temporarily Bars US Drugmaker Hospira from Launching Generic Version of Astellas' Lexiscan

09/27/2022 | 06:25am EST


ę MT Newswires 2022
All news about ASTELLAS PHARMA INC.
11/30Astellas Pharma Plans $360 Million Bond Sale
MT
11/18Aurobindo Pharma Arm Gets US FDA Nod for Amphotericin B Liposome
MT
11/17Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as Fi..
AQ
11/16Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as Fi..
CI
11/08Taysha Gene Therapies, Inc. announced that it has received $79.99982 million in funding..
CI
10/31Global markets live: IAG, Credit Suisse, Foxconn, General Motors, Bl..
MS
10/31Transcript : Astellas Pharma Inc., Q2 2023 Earnings Call, Oct 31, 2022
CI
10/31Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending ..
CI
10/26Actinium Pharmaceuticals' Q4 Phase 3 Trial Updates Could Make Expected Milestones 2023 ..
AQ
10/25Sector Update: Health Care Stocks Hanging on for Small Gain Near Tuesday B..
MT
More news
Financials
Sales 2023 1 480 B 10 622 M 10 622 M
Net income 2023 206 B 1 480 M 1 480 M
Net cash 2023 414 B 2 972 M 2 972 M
P/E ratio 2023 18,7x
Yield 2023 2,82%
Capitalization 3 879 B 27 832 M 27 832 M
EV / Sales 2023 2,34x
EV / Sales 2024 2,17x
Nbr of Employees 14 522
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 2 128,00 JPY
Average target price 2 592,31 JPY
Spread / Average Target 21,8%
EPS Revisions
Managers and Directors
Kenji Yasukawa Chairman, President & Chief Executive Officer
Minoru Kikuoka Chief Financial Officer & Head-Finance
Yoshitsugu Shitaka Chief Scientific Officer & Head-Research
Katsuyoshi Sugita Head-Personnel & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.13.77%27 832
JOHNSON & JOHNSON4.05%465 378
ELI LILLY AND COMPANY31.76%352 592
ABBVIE INC.19.04%284 947
PFIZER, INC.-15.11%281 395
MERCK & CO., INC.43.68%279 198